U.S. may expand Nvidia and AMD’s 15% China chips deal to other companies
Annexon, Inc. (NASDAQ:ANNX), a biotech company currently valued at $264 million, announced Monday it has amended certain common stock purchase warrants originally issued in July 2022. According to a statement based on a Securities and Exchange Commission filing, the amendments extend the term of the warrants by one year to June 30, 2026. InvestingPro analysis suggests the stock is currently undervalued, though the company faces significant operational challenges.
The amended warrants, held by participating investors, are exercisable for up to 6,877,622 shares of Annexon’s common stock. The company stated that the exercise of these warrants is now limited to cash transactions at a price of $5.806875 per share.
If all amended warrants are exercised in full, Annexon would receive aggregate proceeds of approximately $39.9 million, not accounting for any ownership limitations.
The company filed the amendments as an exhibit to its current report on Form 8-K. The filing notes that the summary does not include all details and refers investors to the full amendment document for further information.
This information is based on a press release statement included in Annexon’s SEC filing.
In other recent news, Annexon has reported positive outcomes from its presentations at the Peripheral Nerve Society Annual Meeting, highlighting the potential of its lead investigational therapy, tanruprubart, for treating Guillain-Barré Syndrome (GBS). The therapy showed significant benefits over standard care, with patients experiencing rapid and sustained recovery, particularly in muscle strength, as early as the first week of treatment. These promising results are part of a Phase 3 trial and a real-world evidence study, emphasizing tanruprubart’s potential to transform the treatment landscape for GBS. Meanwhile, Cantor Fitzgerald has maintained its Overweight rating on Annexon, focusing on the company’s upcoming regulatory filings and clinical data. The analysts at Cantor Fitzgerald are monitoring the progress of Annexon’s ANX005, anticipating its Biologics License Application filing and potential approval for GBS treatment. Despite reporting a net loss of $0.37 per share for the first quarter of 2025, Cantor Fitzgerald has increased its earnings per share estimates for Annexon for 2025 and 2026. The firm’s analysis also highlights Annexon’s strong financial position, with $264 million in cash, which could support the development and potential commercialization of its therapies. These developments underscore the ongoing interest in Annexon’s strategic approach and clinical programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.